相似文献
1
Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1.
Br J Haematol. 2025 Apr;206(4):1250-1252. doi: 10.1111/bjh.19959. Epub 2024 Dec 22.
2
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm.
Br J Haematol. 2025 Apr;206(4):1121-1128. doi: 10.1111/bjh.19944. Epub 2024 Dec 19.
3
Olutasidenib: a novel mutant IDH1 inhibitor for the treatment of relapsed or refractory acute myeloid leukemia.
Expert Rev Hematol. 2024 Jun;17(6):211-221. doi: 10.1080/17474086.2024.2354486. Epub 2024 May 21.
4
Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors.
Blood Adv. 2020 Nov 10;4(21):5336-5342. doi: 10.1182/bloodadvances.2020001528.
5
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.
Cancer. 2021 Feb 1;127(3):381-390. doi: 10.1002/cncr.33293. Epub 2020 Oct 29.
6
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms.
Leukemia. 2010 Jun;24(6):1146-51. doi: 10.1038/leu.2010.77. Epub 2010 Apr 22.
7
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial.
Lancet Haematol. 2023 Jan;10(1):e46-e58. doi: 10.1016/S2352-3026(22)00292-7. Epub 2022 Nov 10.
8
Looking Beyond the Surface: Olutasidenib and Ivosidenib for Treatment of mIDH1 Acute Myeloid Leukemia.
Curr Treat Options Oncol. 2024 Nov;25(11):1345-1353. doi: 10.1007/s11864-024-01264-7. Epub 2024 Oct 16.
9
Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders.
Blood Cells Mol Dis. 2015 Mar;54(3):286-91. doi: 10.1016/j.bcmd.2014.11.017. Epub 2014 Nov 26.
10
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.
本文引用的文献
1
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm.
Br J Haematol. 2025 Apr;206(4):1121-1128. doi: 10.1111/bjh.19944. Epub 2024 Dec 19.
2
Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era.
Blood Adv. 2024 Jul 9;8(13):3468-3477. doi: 10.1182/bloodadvances.2024012880.
3
FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation.
Clin Cancer Res. 2024 Apr 1;30(7):1226-1231. doi: 10.1158/1078-0432.CCR-23-2234.
4
A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.
Blood Cancer Discov. 2023 Jul 5;4(4):276-293. doi: 10.1158/2643-3230.BCD-22-0205.
5
Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses.
J Clin Oncol. 2022 Mar 10;40(8):847-854. doi: 10.1200/JCO.21.01548. Epub 2021 Dec 10.
6
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.
Blood. 2015 Mar 19;125(12):1857-65. doi: 10.1182/blood-2014-10-607341. Epub 2015 Jan 26.
7
IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition.
Blood. 2015 Jan 8;125(2):296-303. doi: 10.1182/blood-2013-10-533604. Epub 2014 Nov 14.
8
Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.
Blood. 2013 Oct 17;122(16):2877-87. doi: 10.1182/blood-2013-03-491571. Epub 2013 Aug 16.
9
IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Nature. 2012 Feb 15;483(7390):474-8. doi: 10.1038/nature10860.
10
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Cancer Cell. 2010 Dec 14;18(6):553-67. doi: 10.1016/j.ccr.2010.11.015. Epub 2010 Dec 9.
Zotero 插件